Abbott announced today, that the Company is starting local manufacturing of science-based nutritional products in partnership with Gönenli Süt AŞ, which operates in the Gönen district of Balıkesir.
Since its debut more than 130 years, Abbott has constantly developed life-changing products and solutions in nutrition, diagnostics, medical devices, and branded generic medicines. In 2017, Abbott started full manufacturing of some of its local pharmaceutical product range in Turkey, with plans to reach 90% by 2023. Abbott aims at creating value for Turkey’s healthcare system with its science-based nutrition products as well. Abbott’s manufacturing localization will be part of a 5-year plan, with the first batch expected to be launched on the local market in the first half of 2021. Science-based nutritional products that had been imported into Turkey so far will now be locally produced, including 92% of pediatric products in the first phase of the plan.
Developing science-based nutritional products to support the nutritional needs of people with chronic diseases to keep them strong and active, Abbott embraces the goal to improve the lives of more than 3 billion people globally by the year 2030. To achieve this goal, Abbott prioritizes product innovation, high-quality standards, and sustainable partnerships to deliver long-term impact.
“Our localization project will make significant contributions”
Ebru Kaya, General Manager for Abbott’s nutrition business in Turkey, had this to say: “In the light of Turkey’s 10th Development Plan stating the goal to improve health services and access to medicines, we decided to localize the production of our science-based nutritional products in 2018. Since then, we have been planning our localization process to establish a sustainable organization. We are proud and excited to provide an added value to our economy. We believe that our localization project will make significant contributions to healthcare services in our country.”
